

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

The following list of claims will replace all prior versions and listings of claims in the application.

1-11. (Canceled)

12. (Currently Amended) A method of treating a solid vascularized tumor in a subject in need of such treatment, comprising administering erythropoietin prior to ~~initial~~ administration of a ~~chemotherapeutic agent~~ cisplatin, carboplatin or mitomycin, wherein said erythropoietin is administered in an amount effective to enhance suppression of endothelial growth associated with administration of said ~~chemotherapeutic agent~~ cisplatin, carboplatin or mitomycin, wherein said amount is a dosage in a range of 750 Units per kilogram to 2000 Units per kilogram.

13-18. (Canceled)

19. (Currently Amended) A method according to claim 12 ~~[[15]]~~, wherein said chemotherapeutic agent is administered intravenously.

20. (Currently Amended) A method according to claim 12, wherein said erythropoietin is administered intravenously or subcutaneously.

21. (Currently Amended) A method of treating a solid vascularized tumor in a subject in need of such treatment, comprising administering erythropoietin prior to ~~initial~~ administration of cisplatin;

wherein said erythropoietin is administered in an endothelial-inhibiting amount of, wherein said amount is a dosage in a range from about 750 Units per kilogram to about 2,000 Units per kilogram.

22- 23. (Canceled)

24. (Previously Presented) A method according to claim 21, wherein said cisplatin is administered intravenously.

25. (Currently Amended) A method according to claim 21, wherein said erythropoietin is administered intravenously or subcutaneously.

26. (Currently Amended) A method according to claim 12 ~~[[15]]~~, wherein said ~~chemotherapeutic agent~~ cisplatin, carboplatin or mitomycin is administered in a manner selected from the group consisting of intravenous, intramuscular, intraperitoneal, subcutaneous, intratumor, and intrapleural injection.

27-30. (Canceled)

31. (Previously Presented) A method of treating a solid vascularized tumor according to claim 34, wherein the solid vascularized tumor is a cerebellar hemangioblastoma.

32. (Previously Presented) A method of treating a solid vascularized tumor according to claim 34, wherein the solid vascularized tumor is a ductal carcinoma of the breast.

33. (Previously Presented) A method of treating a solid vascularized tumor according to claim 34, wherein the solid vascularized tumor is a squamous cell cancer of the larynx.

34. (Previously Presented) A method of treating a solid vascularized tumor according to claim 12, wherein said subject is afflicted with a solid vascularized tumor selected from cerebellar hemangioblastoma, ductal carcinoma of the breast or squamous cell cancer of the larynx.

35. (Previously Presented) A method of treating a solid vascularized tumor according to claim 21, wherein said subject is afflicted with a solid vascularized tumor selected from cerebellar hemangioblastoma, ductal carcinoma of the breast, or squamous cell cancer of the larynx.